Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib

Clinical Nuclear Medicine

Volumn 33, Issue 7, 2008, Pages 486-487

  Shinto, Ajit ^a   Nair, Narendra ^a   Dutt, Anil ^a   Baghel, Nawab S ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

CT scan; FDG; GIST; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; STEM CELL FACTOR; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; STEM CELL FACTOR RECEPTOR;

ABDOMINAL PAIN; ADULT; ARTICLE; ASPIRATION CYTOLOGY; CASE REPORT; DRUG RESPONSE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; SINGLE DRUG DOSE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; METABOLISM; METHODOLOGY; MIDDLE AGED; NEEDLE BIOPSY; SCINTISCANNING; TIME;

ANTINEOPLASTIC AGENTS; BIOPSY, FINE-NEEDLE; DIAGNOSTIC IMAGING; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RADIOPHARMACEUTICALS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 52249124564     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31817792a3     Document Type: Article

References (10)

1. Reddy MP, Reddy P, Lilien DL. F-18 FDG PET imaging in gastrointestinal stromal tumor. Clin Nucl Med. 2003;28:677-679.
2. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;10:23:5357-5364.
3. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology. 2005;128:270-279.
4. Tarn C, Godwin AK. The molecular pathogenesis of gastrointestinal stromal tumors. Clin Colorectal Cancer. 2006;6(suppl 1):S7-S17.
5. Gayed I, Vu T, Iyer R, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med. 2004;45:17-21.
6. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998;11:728-734.
7. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of C-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580.
8. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052-1056.
9. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of C-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925-932.
10. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor C-KIT oncoprotein: biological and clinical implications. Oncogene. 2001;20:5054-5058.